brepocitinib tosylate · Priovant Therap · NDA 220106
Lisraya
Earliest generic entry, as listed
19 Aug 2035
Blocked by patent: US 11197867, US 9663526.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11197867 | substance, product | 19 Aug 2035 |
| US 9663526 | substance, product | 19 Aug 2035 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 27 Aug 2031 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 220106 · 001 · RLD | tablet, oral | EQ 30MG BASE | 19 Aug 2035 |